When Your Sponsor Gets Acquired Mid-Trial: The Operational Playbook Sites Need Now
Zymeworks' $929M acquisition of Theravance, whose R&D was already shut down, puts active trial sites in a familiar operational...
Clinical Trial Management System
When Your CRO Gets Acquired Mid-Trial, the Site Pays the Operational Price
Tevogen Bio's MSO/CRO acquisition push signals a consolidation wave that will disrupt site activation, monitoring, and contracts mid-study. Here's...
CTMS BOT: A New Tool for Clinical Trial Automation
In the realm of clinical studies, the nuances and enormous datasets necessitate utmost precision, swift actions, and efficiency. Astellas,...